ECSP22033601A - Formulación de anticuerpo que contiene crizanlizumab - Google Patents

Formulación de anticuerpo que contiene crizanlizumab

Info

Publication number
ECSP22033601A
ECSP22033601A ECSENADI202233601A ECDI202233601A ECSP22033601A EC SP22033601 A ECSP22033601 A EC SP22033601A EC SENADI202233601 A ECSENADI202233601 A EC SENADI202233601A EC DI202233601 A ECDI202233601 A EC DI202233601A EC SP22033601 A ECSP22033601 A EC SP22033601A
Authority
EC
Ecuador
Prior art keywords
crizanlizumab
formulation containing
antibody formulation
antibody
formulations
Prior art date
Application number
ECSENADI202233601A
Other languages
English (en)
Spanish (es)
Inventor
Fabian Bickel
Caroline Hilbert
Juergen Sigg
Frieder Kroener
Maja Anko
Aljosa Jelenko
Francois Griaud
Lina Boado
Dirk Chelius
Rajsekhar Paul
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP22033601A publication Critical patent/ECSP22033601A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ECSENADI202233601A 2019-10-30 2022-04-27 Formulación de anticuerpo que contiene crizanlizumab ECSP22033601A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962927720P 2019-10-30 2019-10-30
US201962927716P 2019-10-30 2019-10-30
US201962933692P 2019-11-11 2019-11-11
US201962936269P 2019-11-15 2019-11-15

Publications (1)

Publication Number Publication Date
ECSP22033601A true ECSP22033601A (es) 2022-05-31

Family

ID=73544317

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202233601A ECSP22033601A (es) 2019-10-30 2022-04-27 Formulación de anticuerpo que contiene crizanlizumab

Country Status (19)

Country Link
US (1) US20220378912A1 (enExample)
EP (1) EP4051236A1 (enExample)
JP (1) JP2023501155A (enExample)
KR (1) KR20220092917A (enExample)
CN (1) CN114828826A (enExample)
AU (1) AU2020373017B2 (enExample)
BR (1) BR112022008097A2 (enExample)
CA (1) CA3158921A1 (enExample)
CL (1) CL2022001085A1 (enExample)
CO (1) CO2022005207A2 (enExample)
EC (1) ECSP22033601A (enExample)
IL (1) IL292403A (enExample)
JO (1) JOP20220097A1 (enExample)
MX (1) MX2022005044A (enExample)
MY (1) MY209141A (enExample)
PE (1) PE20221276A1 (enExample)
PH (1) PH12022551041A1 (enExample)
TW (1) TWI893018B (enExample)
WO (1) WO2021087050A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041957T2 (hu) 2006-12-01 2019-06-28 Novartis Ag Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
JOP20190101A1 (ar) * 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CA3092931A1 (en) * 2018-03-08 2019-09-12 Novartis Ag Use of an anti-p-selectin antibody

Also Published As

Publication number Publication date
IL292403A (en) 2022-06-01
TW202128221A (zh) 2021-08-01
WO2021087050A1 (en) 2021-05-06
CN114828826A (zh) 2022-07-29
MX2022005044A (es) 2022-05-16
CA3158921A1 (en) 2021-05-06
AU2020373017B2 (en) 2024-06-06
PH12022551041A1 (en) 2023-04-24
CO2022005207A2 (es) 2022-05-10
BR112022008097A2 (pt) 2022-08-02
KR20220092917A (ko) 2022-07-04
JOP20220097A1 (ar) 2023-01-30
EP4051236A1 (en) 2022-09-07
JP2023501155A (ja) 2023-01-18
US20220378912A1 (en) 2022-12-01
CL2022001085A1 (es) 2023-02-03
AU2020373017A1 (en) 2022-05-19
MY209141A (en) 2025-06-24
TWI893018B (zh) 2025-08-11
PE20221276A1 (es) 2022-09-05

Similar Documents

Publication Publication Date Title
CL2019003627A1 (es) Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628)
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
SV2018005643A (es) Composiciones de insulina de rapida accion
GT201700184A (es) Nuevas proteínas específicas para pioverdina y pioquelina
MX2020001083A (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
MX2020001885A (es) Formulaciones de daptomicina.
MX2017000764A (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
CL2020000897A1 (es) Composición de proteínas de guisante que tiene calidad nutricional mejorada.
MX2016000405A (es) Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
CO2020016008A2 (es) Formulación de proteína de fusión estable
CO2020016014A2 (es) Formulación de proteína de fusión ctla4-ig
MX2018000264A (es) Formulaciones topicas de diacereina de rheina y sus usos.
MX2020004675A (es) Formulaciones de alcohol de seda.
CL2021000310A1 (es) Composiciones de curcuminoides
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
MX395112B (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
MX2018002514A (es) Citotoxinas modificadas y su uso terapeutico.
BR112019001082A2 (pt) gel intestinal de levodopa e carbidopa e métodos de uso
MX2017013879A (es) Composiciones que comprenden anakinra.
CL2019003801A1 (es) Nuevas formulaciones orales de belinostato.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
ECSP22033601A (es) Formulación de anticuerpo que contiene crizanlizumab
BR112022012436A2 (pt) Formulação compósita e método para preparar a formulação compósita
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação